1. Home
  2. VALN

VALN

Valneva SE

Logo Valneva SE

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-23-2024 2:16pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Founded: 2012 Country:
France
France
Employees: N/A City: N/A
Market Cap: 565.6M IPO Year: 2021
Target Price: $21.50 AVG Volume (30 days): 10.1K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.55 EPS Growth: N/A
52 Week Low/High: $6.58 - $17.05 Next Earning Date: 05-02-2024
Revenue: $170,792,222 Revenue Growth: -57.46%
Revenue Growth (this year): 35.29% Revenue Growth (next year): 7.12%

Share on Social Networks: